ProCE Banner Activity

PI3K/AKT/mTOR Inhibitors and Future Directions in HR+/HER2- Advanced Breast Cancer

Slideset Download
Get up to date on newly approved and emerging agents targeting the PI3K/AKT/mTOR pathway and ESR1 mutations in HR+/HER2- advanced breast cancer, including alpelisib, everolimus, capivasertib, SERDs, and more.

Released: June 17, 2020

Expiration: June 16, 2021

No longer available for credit.

Share

Faculty

Sara M. Tolaney

Sara M. Tolaney, MD, MPH

Chief, Division of Breast Oncology
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Lilly

Faculty Disclosure

Primary Author

Sara M. Tolaney, MD, MPH

Chief, Division of Breast Oncology
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts